Aimei Weixin

Aim Vaccine is a leading full-chain vaccine company in China, covering the entire value chain from research and development to manufacturing and commercialization. As the second-largest vaccine enterprise in China by sales volume (excluding COVID-19 vaccines), the company possesses five advanced technology platforms: mRNA, bacterial vaccine, viral vaccine, genetically engineered vaccine, and combination vaccine. Its commercial portfolio includes widely used vaccines for rabies and hepatitis B, while its extensive pipeline features candidates for COVID-19, pneumococcal diseases, and shingles. Aim Vaccine is notably the first Chinese company to achieve a comprehensive technology stack across all major vaccine modalities, positioning it as a key player in the global infectious disease prevention market. The company is headquartered in Beijing and maintains multiple large-scale GMP-certified manufacturing facilities across China.